secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001628280-22-004490
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin reports 2021 net loss of $60.7M, cash $142.5M; NL-201 interim data expected H2 2022
--------------------------------------------------------------------------------

- Net loss $60.7M in 2021 vs $33.3M in 2020; cash & equivalents $142.5M down from $192.6M; runway into H2 2023.
- Phase 1 interim data for NL-201 in solid tumors expected H2 2022; combination trial with pembrolizumab planned.
- R&D expenses $39.2M (up 61%), G&A $21.5M (up 25%) driven by clinical activities and personnel costs.
- Rohan Palekar (CEO of 89bio) appointed to board; Lewis Williams resigns; Drachman named PFO, Smith named PAO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/nltx-20220225.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-004490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer